MilliporeSigma
All Photos(1)

L-020

Supelco

Levetiracetam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing

Select a Size

Empirical Formula (Hill Notation):
C8H14N2O2
CAS Number:
Molecular Weight:
170.21
EC Number:
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CC[C@H](N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

InChI key

HPHUVLMMVZITSG-LURJTMIESA-N

Gene Information

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
L-023D-111L-031
Levetiracetam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-020

Levetiracetam solution

Levetiracetam-D6 solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-023

Levetiracetam-D6 solution

Levetiracetam-D6 solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-031

Levetiracetam-D6 solution

form

liquid

form

liquid

form

liquid

form

liquid

packaging

ampule of 1 mL

packaging

ampule of 1 mL

packaging

ampule of 1 mL

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

manufacturer/tradename

Cerilliant®

manufacturer/tradename

Cerilliant®

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

concentration

100 μg/mL in methanol

concentration

100 μg/mL in acetonitrile

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

General description

A certified Snap-N-Spike® solution applicable for use in levetiracetam testing methods by LC/MS or GC/MS for applications in clinical toxicology, medication monitoring, urine drug testing, pharmaceutical research, or forensic analysis. Levetiracetam is an antiepileptic drug used in the treatment of epilepsy and is marketed under the trade name Keppra®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Keppra is a registered trademark of UCB Pharma, S.A.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

51.8 °F - closed cup

Flash Point(C)

11.0 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Customers Also Viewed

Slide 1 of 9

1 of 9

Brivaracetam-D3 solution 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Supelco

B-063

Brivaracetam-D3 solution

Levetiracetam-D6 solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-031

Levetiracetam-D6 solution

Oxcarbazepine-13C6 solution 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

O-039

Oxcarbazepine-13C6 solution

Levetiracetam United States Pharmacopeia (USP) Reference Standard

USP

1359404

Levetiracetam

Gabapentin solution 10 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

G-021

Gabapentin solution

Levetiracetam European Pharmacopoeia (EP) Reference Standard

Y0001253

Levetiracetam

Topiramate-D12 solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

T-041

Topiramate-D12 solution

D Consoli et al.
Cerebrovascular diseases (Basel, Switzerland), 34(4), 282-289 (2012-11-07)
Strokes are the leading cause of epileptic seizures in adults and account for 50% of seizures in those over the age of 65 years. The use of antiepileptic drugs to prevent recurrent poststroke seizures is recommended. One hundred and twenty-eight
Radica M Stepanović-Petrović et al.
Anesthesia and analgesia, 115(6), 1457-1466 (2012-11-13)
We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/anti-edematous effects in the same model of localized inflammation and whether opioidergic
Marjolein de Groot et al.
Neuro-oncology, 15(2), 216-223 (2012-12-13)
Treatment of high-grade glioma (HGG) patients with anti-epileptic drugs (AEDs) has met with various side effects, such as cognitive deterioration. The cognitive effects of both older and newer AEDs in HGG patients are largely unknown. The aim of this study
Amy Z Crepeau et al.
Expert review of neurotherapeutics, 10(2), 159-171 (2010-02-09)
Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small
Benjamin W Y Lo et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 38(3), 475-486 (2011-04-26)
New evidence suggests that levetiracetam may be as effective as traditional agents, with better safety profile. To synthesize evidence regarding efficacy and tolerability of levetiracetam as first line, adjunctive or prophylactic antiepileptic agent. Study Selection & Data Extraction: Eligible studies

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service